- Report
- October 2024
- 185 Pages
Global
From €3312EUR$3,545USD£2,802GBP
€3680EUR$3,939USD£3,113GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9342EUR$10,000USD£7,903GBP
- Report
- July 2024
- 107 Pages
Global
From €3500EUR$4,013USD£3,065GBP
Epoetin Beta is a type of hematological drug used to treat anemia caused by chemotherapy, kidney failure, and other conditions. It is a recombinant form of erythropoietin, a hormone produced by the kidneys that stimulates the production of red blood cells. Epoetin Beta is administered intravenously or subcutaneously and is used to increase the number of red blood cells in the body. It is also used to reduce the need for blood transfusions in patients with anemia.
Epoetin Beta is available in both brand-name and generic forms. Brand-name versions include Epogen, Procrit, and Binocrit. Generic versions include Retacrit and NeoRecormon.
Epoetin Beta is manufactured by several companies, including Amgen, Johnson & Johnson, Pfizer, Roche, and Sandoz. Show Less Read more